FMP
PolyPid Ltd.
PYPD
NASDAQ
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
4.3 USD
-0.14 (-3.26%)
About
ceo
Ms. Dikla Czaczkes Akselbrad
sector
Healthcare
industry
Biotechnology
website
https://www.polypid.com
exchange
NASDAQ
Description
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
CIK
0001611842
ISIN
IL0011326795
CUSIP
M8001Q118
Address
18 Hasivim Street
Phone
972 7 4719 5700
Country
IL
Employee
59
IPO Date
Jun 26, 2020
Key Executives
